Transforming Cell Line Development with Syngene’s SynWeave™ Platform

Built on a proprietary CHO cell line and transposon-based technology, SynWeave™ enables the rapid generation of high-yield, stable, and homogeneous clones. The platform integrates advanced clone screening using the Ambr-250 bioreactor, allowing for comprehensive evaluation of titer, key product quality attributes, and process parameters, accelerating your path to robust cell line development.

Syngene’s new biologics facility in the U.S.

Our expanded biologics manufacturing facility in Bayview, Maryland marks a strategic step forward in meeting the growing needs of our global customers. The addition of this facility increases Syngene’s total single-use bioreactor capacity to 50,000 liters, featuring 2,000 and 4,000 liters bioreactors designed to deliver economies of scale.

Your one-stop-shop for XDCs

Syngene offers an integrated bioconjugation platform for XDCs, providing end-to-end support from antibody discovery to GMP manufacturing at up to 1 kg scale. Their expertise covers diverse conjugation technologies, payload and linker chemistry, and advanced analytical and bioassay support. Syngene ensures single-source manufacturing of antibodies, peptides, oligonucleotides, payloads, and linkers, minimizing risk and delays.

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details